Avoid common mistakes on your manuscript.
Correction: Discover Oncology (2023) 14:226 https://doi.org/10.1007/s12672-023-00844-7
After publication an error was found by the authors in the progression-free survival (PFS) analysis. In the original analysis, deaths were not included in the progression-free survival (PFS) analysis as events, as noted in the Methods section. The errors caused by this are listed in this correction article. This analytical error does not affect the interpretation and conclusions of the original article [1].
Abstract
Incorrect
-
The 3-year OS, PFS, and CSS were 80.9% (95% confidence interval [CI]: 64.8–90.7), 68.3% (95% CI 51.8–81.2), and 85.0% (95% CI 68.7–93.4), respectively.
Correct
-
The 3-year OS, PFS, and CSS were 80.9% (95% confidence interval [CI]: 64.8–90.7), 58.9% (95% CI: 42.7–73.3), and 85.0% (95% CI: 68.7–93.4), respectively.
Results
Incorrect
-
With a median follow-up period of 36 months (range: 1–156), the 3-year and 5-year OS rates were 80.9% (95% CI 64.8–90.7) and 69.7% (51.6–83.2), respectively (Fig. 1A). The 3-year and 5-year PFS rates were 68.3% (95% CI 51.8–81.2) and 68.3% (51.8–81.2), respectively, and those for the CSS rates were 85.0% (95% CI 68.7–93.4) and 73.3% (54.5–86.3), respectively (Fig. 1B, C).
-
In an analysis limited to 12 patients aged ≥ 75 years, the median follow-up period was 32.5 months (range: 2–77). The 3-year and 5-year OS rates were the same, 87.5% (95% CI 46.3–98.3), and the 3- and 5-year PFS rates were also the same, 53.3% (95% CI 53.3–98.6) (Fig. 2A, B).
Correct
-
With a median follow-up period of 36 months (range: 1–156), the 3-year and 5-year OS rates were 80.9% (95% CI 64.8–90.7) and 69.7% (51.6–83.2), respectively (Fig. 1A). The 3-year and 5-year PFS rates were 58.9% (95% CI: 42.7–73.3) and 55.6% (39.4–70.7), respectively, and those for the CSS rates were 85.0% (95% CI: 68.7-93.4) and 73.3% (54.5-86.3), respectively (Fig. 1B, C).
-
In an analysis limited to 12 patients aged ≥75 years, the median follow-up period was 32.5 months (range:2-77). The 3-year and 5-year OS rates were the same, 87.5% (95% CI 46.3–98.3), and the 3- and 5-year PFS rates were also the same, 77.1% (95% CI 40.5–94.4) (Fig. 2A, B).
Incorrect
-
The median age of the 49 patients was 72 years (range: 70–78) years.
Correct
-
The median age of the 49 patients was 72 years (range: 70–78 years).
Incorrect figure 1b
Correct figure 1b
Incorrect figure 2b
Correct figure 2b
Reference
Uchinami Y, Yasuda K, Kano S, Otsuka M, Hamada S, Suzuki T, Tsushima N, Takahashi S, Fujita Y, Miyazaki T, Higaki H, Taguchi J, Shimizu Y, Sakashita T, Homma A, Aoyama H. Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma. Discover Oncol. 2023;14:226. https://doi.org/10.1007/s12672-023-00844-7.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Uchinami, Y., Yasuda, K., Kano, S. et al. Correction: Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma. Discov Onc 15, 18 (2024). https://doi.org/10.1007/s12672-024-00868-7
Published:
DOI: https://doi.org/10.1007/s12672-024-00868-7